Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BRISC and BRCA1-A complex member 2 (BABAM2) is a scaffold/adaptor protein integral to two large multi-protein complexes, BRCA1-A and BRISC, which participate in cell responses to DNA double-strand breaks. BABAM2 functions to stabilize these complexes and facilitate the removal of Lys63-linked ubiquitin chains at DNA damage sites, ensuring effective recruitment and regulation of BRCA1, cell cycle checkpoint activation, and maintenance of genomic stability. As part of the BRCA1-A complex, BABAM2 (also called BRE/BRCC45/MERIT40) interacts with tumor necrosis factor receptor-1 and acts as an anti-apoptotic protein. Genetic alterations in BABAM2 have been linked to altered breast cancer susceptibility, making it an important candidate for targeted research and possibly future therapeutics in cancers with DNA repair defects[1][2][3]. There are currently no known small-molecule or biologic drugs that directly target BABAM2, nor are there clinically established safety concerns specific to therapeutic targeting of BABAM2. However, its essential roles in DNA repair and apoptosis suggest that disruption can impact genome stability and cell viability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BRISC and BRCA1-A complex member 2 (BABAM2).